- Home
- ZYME vs AMSC Comparison
ZYME vs AMSC Comparison
Compare ZYME & AMSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- AMSC
- Stock Information
- Founded
- ZYME 2003
- AMSC 1987
- Country
- ZYME United States
- AMSC United States
- Employees
- ZYME N/A
- AMSC N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- AMSC Metal Fabrications
- Sector
- ZYME Health Care
- AMSC Consumer Discretionary
- Exchange
- ZYME Nasdaq
- AMSC Nasdaq
- Market Cap
- ZYME 846.1M
- AMSC 793.5M
- IPO Year
- ZYME 2017
- AMSC 1991
- Fundamental
- Price
- ZYME $11.31
- AMSC $21.60
- Analyst Decision
- ZYME Buy
- AMSC Strong Buy
- Analyst Count
- ZYME 6
- AMSC 3
- Target Price
- ZYME $19.50
- AMSC $33.67
- AVG Volume (30 Days)
- ZYME 553.2K
- AMSC 401.9K
- Earning Date
- ZYME 05-08-2025
- AMSC 05-28-2025
- Dividend Yield
- ZYME N/A
- AMSC N/A
- EPS Growth
- ZYME N/A
- AMSC N/A
- EPS
- ZYME N/A
- AMSC 0.09
- Revenue
- ZYME $93,384,000.00
- AMSC $198,191,000.00
- Revenue This Year
- ZYME $26.29
- AMSC $51.58
- Revenue Next Year
- ZYME $75.78
- AMSC $16.67
- P/E Ratio
- ZYME N/A
- AMSC $238.03
- Revenue Growth
- ZYME 85.05
- AMSC 46.42
- 52 Week Low
- ZYME $8.21
- AMSC $13.07
- 52 Week High
- ZYME $17.70
- AMSC $38.02
- Technical
- Relative Strength Index (RSI)
- ZYME 40.96
- AMSC 61.07
- Support Level
- ZYME $10.86
- AMSC $20.13
- Resistance Level
- ZYME $13.23
- AMSC $21.64
- Average True Range (ATR)
- ZYME 0.56
- AMSC 0.99
- MACD
- ZYME -0.10
- AMSC 0.31
- Stochastic Oscillator
- ZYME 18.78
- AMSC 93.62
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet world's demand for smarter, cleaner and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.